

54. (New) The composition according to claim 52, wherein the immune response enhancer is selected from the group consisting of Montanide ISA50, Seppic Montanide ISA 720, a cytokine, a microsphere, dimethyl dioctadecyl ammoniumbromide (DDA) based adjuvants, AS-1, AS-2, Ribi Adjuvant system based adjuvant, QS21, saponin based adjuvants, Syntex adjuvant in its microfluidized form, MV, ddMV, immune stimulating complex (iscom) based adjuvants, and inactivated toxins.

55. (New) The composition of claim 54, wherein said cytokine is selected from the group consisting of GM-CSF and Flt3-ligand.

### REMARKS

Claims 4, 5, 8, and 9 have been cancelled from the application, claims 1, 2, 3, 6, and 7 have been amended, and new claims 47-55 have been added. Support for all the above amendments may be found throughout the specification as originally filed and none of the amendments constitutes new matter. In particular, support for between 1 and 3 amino acid positions within the immunogenic portion, such that the ability of the variant to react with WT1-specific antisera and/or T-cell lines or clones is enhanced relative to a native WT1 can be found, for example, on page 3, lines 15-20 and in original claim 9. Support for the His tag of SEQ ID NO:335 can be found, for example, in Example 8 on page 103 and in the sequence listing. Support for amino acid residues 117-139 and 130-138 can be found, for example, on page 57, Table I, and page 99, Table XLVIII, respectively. Support for immune response enhancers can be found, for example, on page 40, lines 17-26. Attached is a version with markings to show changes made.

Following this amendment, claims 1-3, 6, 7, and 47-54 are under examination. Favorable consideration of the present application in view of the above amendment is respectfully requested.

Respectfully submitted,

Alexander Gaiger et al.

Seed Intellectual Property Law Group PLLC

  
Julie A. Urvater, Ph.D.

Registration No. 50,461

Enclosure:  
Postcard

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031  
D:\NrPortbl\iManage\JUDYD\308894\_1.DOC



VERSION WITH MARKINGS TO SHOW CHANGES MADE

RECEIVED

SEP 23 2002

TECH CENTER 1600/2900

In the Claims:

Claims 4, 5, 8, and 9 have been cancelled.

New claims 47-55 have been added.

Claims 1, 2, 3, 6, and 7 have been amended as follows:

1. (Amended) A polypeptide comprising at least an immunogenic portion of ~~a native WT1~~ an amino acid sequence of SEQ ID NO:335, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with WT1-specific antisera and/or T-cell lines or clones is not substantially diminished, ~~wherein the polypeptide comprises no more than 16 consecutive amino acid residues present within a native WT1 polypeptide.~~

2. (Amended) A polypeptide according to claim 1 or claim 47, wherein the immunogenic portion binds to an MHC class I molecule.

3. (Amended) A polypeptide according to claim 1 or claim 47, wherein the immunogenic portion binds to an MHC class II molecule.

6. (Amended) A polypeptide according to claim 1 or claim 47, wherein the polypeptide comprises 4-16 consecutive amino acids of a native WT1 polypeptide.

7. (Amended) A polypeptide according to claim 1 or claim 47, wherein the polypeptide comprises 8-10 consecutive amino acids of a native WT1 polypeptide.